AA
ADMA icon

AlphaCentric Advisors’s ADMA Biologics ADMA Stock Holding History

AlphaCentric Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$90.4K Sell
10,037
-8,745
-47% -$138K 0.09% 221
2025
Q4 		$343K Buy
+18,782
New +$317K 0.34% 94

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

AlphaCentric Advisors's ADMA Position: Q1 2026 in Review

AlphaCentric Advisors reduced its ADMA Biologics (ADMA) stake by 47% in Q1 2026, selling an estimated $138K and leaving 10,037 shares worth $90.4K. The position accounts for 0.09% of the portfolio, ranked #221.

AlphaCentric Advisors first reported a position in ADMA in Q4 2025 and has held it in 2 quarters since. The position peaked at $343K in Q4 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • AlphaCentric Advisors held 10,037 shares of ADMA Biologics worth $90.4K as of Q1 2026.
  • AlphaCentric Advisors sold 8,745 ADMA Biologics shares in Q1 2026, an estimated $138K.
  • ADMA Biologics made up 0.09% of AlphaCentric Advisors's portfolio in Q1 2026, its #221 holding.
  • AlphaCentric Advisors first reported a position in ADMA Biologics in Q4 2025 and has held it in 2 quarters since.
  • AlphaCentric Advisors's ADMA Biologics position peaked at $343K in Q4 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.